Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.
Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.
复制标题
DOI：
10.1155/2017/1928021
复制
发表时间：
2017
影响因子：
--
通讯作者：
Ko YH
中科院分区：
文献类型：
--
作者：
Lee JS;Ahn YH;Won HS;Sun S;Kim YH;Ko YH
背景/目的。miRNA-200 （miR-200）家族可能是上皮细胞向间质转化的关键抑制剂。然而，miR-200s在各种人类恶性肿瘤中的潜在预后价值仍存在争议。该荟萃分析分析了多种肿瘤中miR-200水平与生存结果之间的关系。方法。通过检索Embase、PubMed、CINAHL和谷歌学者数据库确定符合条件的已发表研究。合并患者临床资料，并使用95%置信区间（95% CI）的合并风险比（hr）来计算这种关联的强度。结果。汇总的HR表明，在34篇符合条件的文章中，miR-200家族成员的高组织表达与更好的生存相关（总生存[OS]: HR = 0.70, 95% CI 0.54-0.91；无进展生存[PFS]: HR = 0.63, 95% CI 0.52-0.76）。相反，循环miR-200成员的高表达与不良临床结果显著相关（OS, HR = 1.68, 95% CI 1.15-2.46； PFS, HR = 2.62, 95% CI 1.68 - 4.07）。结论。这项荟萃分析的结果表明，miR-200家族成员是各种癌症患者的潜在预后生物标志物。为了将这些发现应用于临床，需要进行大量的前瞻性研究来验证miR-200s在个体癌症类型中的预后价值。
Background/Aims. The miRNA-200 (miR-200) family may act as key inhibitors of epithelial-to-mesenchymal transition. However, the potential prognostic value of miR-200s in various human malignancies remains controversial. This meta-analysis analyzed the associations between miR-200 levels and survival outcomes in a variety of tumors. Methods. Eligible published studies were identified by searching the Embase, PubMed, CINAHL, and Google scholar databases. Patient clinical data were pooled, and pooled hazard ratios (HRs) with 95% confidence intervals (95% CI) were used to calculate the strength of this association. Results. The pooled HRs suggested that high tissue expression of miR-200 family members was associated with better survival (overall survival [OS]: HR = 0.70, 95% CI 0.54–0.91; progression-free survival [PFS]: HR = 0.63, 95% CI 0.52–0.76) in thirty-four eligible articles. In contrast, higher expression of circulating miR-200 members was significantly associated with poor clinical outcome (OS, HR = 1.68, 95% CI 1.15–2.46; PFS, HR = 2.62, 95% CI 1.68–4.07). Conclusion. The results from this meta-analysis suggest that miR-200 family members are potential prognostic biomarkers in patients with various carcinomas. To apply these findings in the clinic, large prospective studies are needed to validate the prognostic values of miR-200s in individual cancer types.